help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujita, Y.
Right arrow Articles by Ochi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, Y.
Right arrow Articles by Ochi, T.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 1 425-431
Copyright © 2000 by The Endocrine Society


Original Studies

Novel Mutations of the Cathepsin K Gene in Patients with Pycnodysostosis and Their Characterization

Yoshi Fujita, Ken Nakata, Natsuo Yasui, Yoshito Matsui, Eiichiro Kataoka, Kazuo Hiroshima, Ryo-ichi Shiba and Takahiro Ochi

Department of Orthopedic Surgery, Osaka University Medical School (Y.F., K.N., N.Y., E.K., T.O.), Suita City, Osaka 565-0871; the Department of Orthopedic Surgery, Osaka Medical Center for Maternal and Child Health (Y.M.), Izumi-City, Osaka 594-1101; the Department of Orthopedic Surgery, Osaka National Hospital (K.H.), Osaka City, Osaka 540-0006, and the Department of Orthopedic Surgery, Hyogo Nojigiku Medical Center for Disabled Children (R.S.), Kobe-City, Hyogo 651-2215, Japan

Address all correspondence and requests for reprints to: Dr. Yoshi Fujita, Department of Orthopedic Surgery, Osaka University Medical School, 2–2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: yfujita{at}ort.med.osaka-u.ac.jp


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Pycnodysostosis is a rare autosomal recessive skeletal dysplasia characterized by short stature, osteosclerosis, acroosteolysis, bone fragility, and skull deformities. Recently, mutations in the gene encoding cathepsin K (CK), a lysosomal cysteine protease localized exclusively in osteoclasts, were found to be responsible for this disease. We analyzed genomic DNA from four unrelated Japanese patients with this disorder and identified three different mutations of their CK genes: a previously reported missense mutation (A277 V), a novel single base deletion mutation (531 del T) causing a frame shift from codon 142 that results in a premature termination codon, and a novel missense mutation (L9P) in the signal peptide region. To investigate whether the L9P mutation disrupts signal peptide function and decreases protein synthesis, mutant and wild-type CK complementary DNAs driven by the cytomegalovirus promoter were transfected into COS-7 cells, and their gene products were detected by immunohistochemistry and Western blotting. Expression of the mutant protein was markedly reduced, suggesting decreased mature CK production in this patient, which may have been due to dysfunction of the signal peptide. These results provide evidence that a structural change in the signal peptide of the CK protein was involved in the pathogenesis of pycnodysostosis.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
PYCNODYSOSTOSIS is an uncommon, autosomal recessive skeletal dysplasia with a uniform clinical phenotype characterized by short stature, osteosclerosis, acroosteolysis of the distal phalanges, clavicular dysplasia, bone fragility, and skull deformities with delayed suture closure (1). Maroteaux and Lamy speculated that the French artist and aristocrat Henri de Toulouse-Lautrec suffered from pycnodysostosis (2). To date, more than 150 patients have been reported, most of whom were the offspring of nonconsanguinous parents (3). The gene encoding this phenotype has been mapped to human chromosome 1q21 by genetic linkage analysis (4, 5), and the responsible gene was recently identified by a positional cloning strategy, as cathepsin K (CK), a lysosomal cysteine protease (6). To date, 10 mutations disrupting the structure of pro and mature CK protein have been reported in 12 unrelated pycnodysostosis families (6, 7, 8, 9). CK is a member of the papain-cysteine protease family and is known to degrade bone matrix proteins, type I and type II collagen, osteopontin, and osteonectin at low pH (10, 11). It has been cloned from human, rabbit, and murine osteoclast libraries (12, 13, 14, 15, 16, 17). By means of in situ hybridization and immunolocalization, CK has been shown to be highly expressed in human osteoclasts (12, 14, 15). Its selective presence in the osteoclast suggests that CK plays a major role in bone resorption, and consequently may present a potential target for therapeutic intervention in diseases involving excessive bone loss. Recently, Saftig et al. generated CK-deficient mice by targeted inactivation of the CK gene (18). These mice display an osteopetrotic phenotype, and their ultrastructural, histological, and radiological abnormalities closely resemble those described for pycnodysostosis.

In this study we analyzed the sequence of the coding region of the CK gene in four patients from unrelated families and identified three different mutations of the CK gene. Three patients had mutations altering the amino acid sequence of the mature peptide, and one patient had an amino acid substitution in the signal peptide region of this protein. We examined the expression of this mutant CK protein in COS-7 cells using a transient expression assay. The signal peptide mutation detected in our patient was a new type of mutation disrupting the function of CK protein.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Patients

Four Japanese patients were studied. Patients 1, 3, and 4 were men, aged 32, 36, and 37 yr, respectively. Patient 2 was a 54-yr-old woman. They were all unrelated. Patients 1 and 4 were the offspring of the nonconsanguinous parents and were unaware of any congenital anomalies in their families. Parents of patients 2 and 3 were the first cousins, respectively. All four patients showed characteristic clinical findings, such as short stature, frequent fractures, osteosclerosis, skull deformities, and acroosteolysis of the distal phalanges. There was no phenotypical difference among these cases, and they all showed similar radiographic features (Fig. 1Go).



View larger version (117K):
[in this window]
[in a new window]
 
Figure 1. Skeletal radiographs of patient 4 (a 34-yr-old male). a, Anteroposterior view of the skull. Open cranial sutures can be seen (arrow). b, Anteroposterior view of the hand. Note dissolution of the distal phalanges (arrows).

 
Preparation of DNA

Whole blood was obtained from each patient as well as from the parents and sister of patient 4. Blood samples from 80 normal individuals were used as a control. Genomic DNA was extracted from whole blood samples using the DNA Extraction Kit (Stratagene, La Jolla, CA) according to the manufacturer’s recommendations. CK genomic DNA were amplified in 6 overlapping fragments by genomic DNA PCR. A 1.6-kbp product, corresponding to nucleotides (nt) 29–225 interrupted by intron 1, was amplified using the forward primer (PR-1) 5'-TAA ATC TAG CAC CCC TGA TGG-3' and the reverse primer (PR-2) 5'-CTT GTT GTT ATA TTG CTT CCT GTG GG-3'. A 0.9-kbp product, corresponding to nt 139–471 interrupted by introns 2 and 3, was amplified using the forward primer (PR-3) 5'-GTG AGC TTT GCT CTG TAC CCT-3' and the reverse primer (PR-4) 5'-TCG ATA GTC GAC AGA GTC TGG-3'. A 2.0-kbp product, corresponding to nt 362–697 interrupted by intron 4, was amplified using the forward primer (PR-5) 5'-TGG TTC AGA AGA TGA CTG GAC-3' and the reverse primer (PR-6) 5'-CAG AGT CAA TAC CCC GGT TCT-3'. A 4.6-kbp product, corresponding to nt 580–881 interrupted by intron 5, was amplified using the forward primer (PR-7) 5'-CTC TTA AAT CTG AGT CCC CAG-3' and the reverse primer (PR-8) 5'TAA AAC TGG AAG GAG GTC AGG-3'. A 0.5-kbp product, corresponding to nt 756–980 interrupted by intron 6, was amplified using the forward primer (PR-9) 5'-GGC AGC TAA ATG CAG AGG GTA-3' and the reverse primer (PR-10) 5'-CAG TGC TTG TTT CCC TTC TGG-3'. A 2.5-kbp product, corresponding to nt 917-1155 interrupted by intron 7, was amplified using the forward primer (PR-11) 5'-GCG ATA ATC TGA ACC ATG CGG-3' and the reverse primer (PR-12) 5'-TCG TTA CAC TGC ACC ATC GTG-3'. The PCR conditions to amplify the 4.6-kbp product were 30 cycles of 96 C for 1 min, 65 C for 1 min, and 72 C for 3 min. The other products were amplified for 30 cycles at 96 C for 1 min, 63 C for 1 min, and 72 C for 2 min. Each product was used for direct sequencing or subcloned into the pCR 2.1 vector using an Original TA Cloning Kit (Invitrogen, San Diego, CA). Positive clones were selected, and isolated plasmids were used for sequencing on an automated fluorescence-based sequencer (ABI, Perkin Elmer Corp., Foster City, CA).

Ribonucleic acid (RNA) extraction, RT-PCR, and PCR amplification of CK complementary DNA (cDNA)

RNA was prepared from fracture callus and cultured bone marrow cells of patient 4. Callus was harvested at the time of surgery for a fractured right femur. Total RNA was extracted with guanidinium thiocyanate followed by centrifugation in CsCl. Bone marrow blood samples was also obtained from patient 4, and bone marrow cells were cultured for 14 days in {alpha}MEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10-8 mol/L 1{alpha},25-hydroxyvitamin D3, 10% FBS, and 10% autologous bone marrow supernatant to induce the osteoclastic phenotype (19, 20). Total RNA was extracted using the phenol/guanidine isothiocyanate method (Trizol reagent, Life Technologies, Inc.). cDNA was synthesized using oligo-(deoxythymidine) primers and the Superscript II preamplification system (Life Technologies, Inc.). CK cDNA was amplified in two overlapping fragments by cDNA PCR. A 569-bp product, corresponding to nt 71–639 of exons 1–5, was amplified using the forward primer (PR-13) 5'-GAA ACG AAG CCA GAC AAC AG-3' and the reverse primer (PR-14) 5'-TCC ACA GCC ATC ATT CTC AG-3'. A 576-bp product, corresponding to nt 563-1138 of exons 5–8, was amplified using the forward primer (PR-15) 5'-AGA AGA AAA CTG GCA AAC TC-3' and the reverse primer (PR-16) 5'-CGT GGA AGA AAT GGA AGA GC-3'. In addition, a 1068-bp product, corresponding to nt 71–1138 of exons 1–8, was amplified using forward primer PR-13 and reverse primer PR-16. The PCR conditions to amplify the 569- and 576-bp products were 30 cycles of 96 C for 1 min, 60 C for 1 min, and 72 C for 1 min. The PCR conditions for the 1068-bp product were 30 cycles of 96 C for 1 min, 60 C for 1 min, and 72 C for 2 min. The amplified products were subjected to direct sequencing or were subcloned into pCR 2.1 vector. Positive clones were selected, and the isolated plasmids were used for sequencing.

Transient expression of wild-type and mutant CK genes tagged with FLAG in COS-7 cells

The entire cDNA of the nt 131C mutant and wild-type CK genes tagged at the COOH-terminus with a FLAG epitope was constructed as follows. First, a PCR fragment containing the full coding sequence of the nt 131C mutated CK was amplified from the cDNA of patient 3 with a sense primer containing an EcoRI site (PR-17, 5'-CCG GAA TTC GAA ACG AAG CCA GAC AAC AGA TTT CC-3'), and an antisense primer containing a FLAG sequence, termination codon, and EcoRI site (PR-18, 5'-CCG GAA TTC GAG TCA CTT GTC ATC GTC GTC CTT GTA GTC CAT CTT GGG GAA GCT GGC CAG GTT GGC-3'). A single point mutation (C to T) was introduced at nt 131 of the mutant CK cDNA using oligonucleotide-directed mutagenesis (21). Consequently, wild-type CK cDNA was obtained. The wild-type and mutant CK cDNAs tagged with FLAG were subcloned in pcDNA3.1 (Invitrogen) and were designated pCK-FLAG and pL9PCK-FLAG. All DNA constructs were verified by sequencing.

COS-7 cells were maintained and propagated in DMEM containing 10% FBS (Life Technologies, Inc.) at 37 C in 95% room air and 5% CO2 with a humidity of 100%. One day before transfection the cells were trypsinized and plated into six-well cell culture dishes. When the cells reached a density of 70–80%, they were transfected with 2 µg plasmid DNA using 3 µl FuGene 6 Transfection Reagent (Roche Molecular Biochemicals, Mannheim, Germany).

Immunohistochemical staining and Western blotting

At 48 h after transfection, COS-7 cells were fixed with 4% paraformaldehyde for 30 min at room temperature, permeabilized with 0.04% Triton X-100, and incubated with anti-FLAG Bio-M2 antibody (10 µg/ml; Sigma, St. Louis, MO) at room temperature for 1 h. This was followed by incubation with avidin labeled with fluorescein isothiocyanate (10 µg/ml; EY Laboratories, Inc., San Mateo, CA) at room temperature for 1 h. The cells were washed in PBS, mounted in glycerol, and examined with a fluorescence microscope. In addition, after incubation with the primary antibody, the immunoreaction was visualized by incubation with avidin-biotin-peroxidase complex (Vectastain Elite ABC kit, Vector Laboratories, Inc., Burlingame, CA) for 30 min and with diaminobenzidine solution containing 0.01% H2O2 for 10 min. The cells were examined under a light microscope.

For Western blotting, the cells were harvested at 48 h after transfection, and COS-7 cell homogenates were resolved on 4–20% gradient polyacrylamide gel and transferred to nitrocellulose filters. FLAG-tagged CK protein was detected using anti-FLAG Bio-M2 antibody. The approximate molecular size of the protein was determined by comparison with ECL molecular weight standards (Amersham Pharmacia Biotech, Aylesbuy, UK).

In all cases, mock-transfected COS-7 cells were used as the control.

mRNA extraction and RT-PCR

At 48 h after transfection, cells were harvested, and mRNA was extracted using the Micro-FastTrack kit (Invitrogen). RNA was reverse transcribed, and the cDNA was immediately amplified using forward primer PR-17 and reverse primer PR-19 (5'-CTT GTC ATC GTC GTC CTT GTA GTC-3'), a primer pair specific for FLAG-tagged CK. The PCR conditions were 30 cycles of 94 C for 1 min, 63 C for 1 min, and 72 C for 2 min. PCR amplification of the glyceraldehyde-3-phosphate dehydrogenase gene was also performed.


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Identification of the mutation

CK genomic DNA was amplified as six overlapping fragments by the genomic DNA PCR. After cloning into the pCR 2.1 vector, the entire coding region of CK genomic DNA was sequenced.

Patient 1 revealed the presence of a C to T transition of nt 935 in exon 7. Direct sequencing of genomic DNA showed that the patient was homozygous for this mutation. This point mutation resulted in the substitution of an Ala277 by a Val (A277V) in the mature CK polypeptide (Fig. 2aGo).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 2. Direct sequencing of CK gene obtained from patients 1, 2, and 3 compared to those from an unrelated normal control. a, The missense mutation A277V was found in patient 1. b, A 1-bp deletion at nt 531 was found in patients 2 and 3.

 
Patients 2 and 3 had a same 1-bp deletion of nt 531 in exon 5 (531 del T; Fig. 2bGo). Direct genomic sequencing showed that the patient was also homozygous for this mutation, which resulted ina frame shift from codon 142 and a premature stop at codon 160.

Direct sequencing of genomic DNA indicated that patient 4 was homozygous for a T to C transition at nt 131 in exon 2, which replaced the normal Leu9 (CTA) with a Pro (CCA) (L9P) in the signal peptide of CK (Fig. 3Go). No mutations was found in the other amplified DNA fragments. The patient’s parents were heterozygous for this mutation, and the unaffected sister was homozygous for the normal gene (Fig. 3Go). This base substitution was not detected in any of the 80 normal controls by direct sequencing of this region of the CK gene, suggesting that it was unlikely to be a neutral polymorphism. Sequencing of the cDNA of patient 4 transcribed from fracture callus and from cultured bone marrow cells showed the same mutation. No other mutations were found in the amplified cDNA fragments.



View larger version (38K):
[in this window]
[in a new window]
 
Figure 3. CK gene mutation detected by genomic DNA sequencing in patient 4. The missense mutation L9P was detected. Solid symbols denote affected subjects, half-solid symbols denote unaffected heterozygous, circles denote female family members, and squares indicate male family members.

 
Expression of wild-type and mutant CK genes tagged with FLAG in COS-7 cells

Immunohistochemical staining using a monoclonal FLAG antibody revealed immunoreactivity in the cytoplasm of the cells transfected with pCK-FLAG (Fig. 4aGo). No immunoreactivity was detected in cells transfected with pL9PCK-FLAG and mock-transfected COS-7 cells (Fig. 4Go, b and c). The same results were obtained by avidin-biotin-peroxidase immunohistochemistry (data not shown).



View larger version (101K):
[in this window]
[in a new window]
 
Figure 4. Immunohistochemical analysis of expression of the wild-type and L9P mutant FLAG-tagged CK genes. On fluorescence immunohistochemistry, the immunoreaction was positive in the cytoplasm of cells transfected with pCK-FLAG (a), and that of cells transfected with pL9PCK-FLAG was negative (b), as was that of mock-transfected COS-7 cells (c).

 
Western blotting was performed with the monoclonal FLAG antibody (Fig. 5Go). In homogenates of COS-7 cells transfected with pCK-FLAG, a protein band of 37 kDa, the approximate molecular mass for the pro-CK, was detected. In homogenates of COS-7 cells transfected with pL9PCK-FLAG, only a trace of this protein was detected, and no immunoreactivity was detected in homogenates of mock-transfected COS-7 cells. To determine whether the reduced expression of CK was due to a defect at the transcriptional or translational level, we performed RT-PCR analysis of RNA isolated from COS-7 cells transfected with normal CK or the L9P mutant (Fig. 6Go). The expected 1061-bp product was amplified from both wild-type and mutant mRNA. No difference in the density of the amplified PCR products was observed between the pCK-FLAG and pL9PCK-FLAG transfectants.



View larger version (49K):
[in this window]
[in a new window]
 
Figure 5. Western blots of COS-7 cells transfected with the wild-type and L9P mutant FLAG-tagged CK genes. COS-7 cells were transfected with pCK-FLAG and pL9PCK-FLAG and processed for Western blotting as described in Materials and Methods. An equal amount of protein (50 µg) was loaded into each lane, and a monoclonal FLAG antibody was used for detection. mut, COS-7-cells transfected with pL9PCK-FLAG; wt, COS-7 cells transfected with pCK-FLAG; con, mock-transfected COS-7-cells; M, ECL molecular weight marker. ß-Actin is shown in the lower panels. The expression of mutant FLAG-tagged CK was markedly reduced compared to that of wild-type CK.

 


View larger version (51K):
[in this window]
[in a new window]
 
Figure 6. RT-PCR amplification of mRNA extracted from COS-7 cells transfected with pCK-FLAG and pL9PCK-FLAG. mut, COS-7-cells transfected with pL9PCK-FLAG; wt, COS-7 cells transfected with pCK-FLAG; con, COS-7-cells transfected with pCDNA3.1; N, negative control. Amplification with primers specific for FLAG-tagged CK is shown in the upper panel. The expected 1061-bp product was amplified from both wild-type and mutant mRNA. No differences in the amplified PCR products were seen between the wild-type and mutant mRNAs. Amplification of glyceraldehyde 3-phosphate dehydrogenase RNA from the same samples is shown in the lower panel.

 

    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Mutations of the CK gene were detected in all of the patients with pycnodysostosis who we studied. Patient 1 had a C to T transition at nt 935, predicting an Ala to Val substitution at residue 277 (A277V). Gelb et al. previously reported this mutation in an apparently unrelated patient who has Belgian and mixed Belgian, Algerian parents (Fig. 7Go) (8). This was the third mutation reported at nt 935, after two reports of an Ala to Gln substitution by C to A transition at the same site, suggesting that nt 935 is a mutational hot spot for pycnodysostosis (9). No A277V mutation was detected in analysis of more than 50 normal individuals by Hou et al. They also performed the expression analysis and showed that the A277V mutation resulted in a precursor protein lacking autoactivating function and unstable in the presence of pepsin (9).



View larger version (13K):
[in this window]
[in a new window]
 
Figure 7. The structure of the CK cDNA and the sites of mutation in pycnodysostosis. The top line represents the cDNA. The locations of three mutations identified in present study are indicated below the cDNA. The normal CK polypeptide is shown with the pre-, pro-, and mature peptides. The three residues in the active site conserved among all members of the cysteine protease superfamily are indicated below the normal polypeptide. The missense mutation A277V, found in patient 1, has been reported previously. The 1-bp deletion at nt 531, found in patients 2 and 3, caused a frame shift, with the predicted truncation of the mature peptide eliminating two active site residues. The missense mutation L9P, found in patient 4, was located in the prepeptide.

 
Patients 2 and 3 had a 1-bp deletion at nt 531. This novel mutation resulted in a frame shift and truncation of the mature peptide at codon 160. CK is a member of the papain protease family and has a conserved triad of amino acids involved in proteolytic catalysis, which are Cys139, His276, and Asn296 (Fig. 7Go) (10). Therefore, the truncated protein was considered to be biologically inactive, because it lacked two of the three amino acids that are essential for catalytic activity. It also lacked four of the six cysteines that are predicted to be important in the formation of intramolecular disulfide bonds.

In patient 4, we characterized a novel missense mutation of CK, a T to C transition, at nt 131 in exon 2, which replaced Leu (CTA) in codon 9 with Pro (CCA; Fig. 7Go). This mutation was not located in the coding region of the mature protein, but in the signal peptide of prepro-CK. Signal peptides play a critical role in the targeting of proteins to the endoplasmic reticulum and translocation of proteins across the membrane (22, 23). They typically have three distinct domains: a positively charged amino-terminal region (N-region), a central hydrophobic core (H-region), and a more polar carboxyl-terminal domain (C-region) (23). The signal peptide sequence of CK contains a positively charged amino acid (Lys5) close to the initial methionine and a subsequent stretch of hydrophobic amino acids terminated by a consensus alanine (Ala15) (10). Substitution of amino acid 9 may disrupt the hydrophobic core of the signal peptide of the CK.

The functional properties of the L9P mutant of CK were examined by transient expression in COS-7 cells. The L9P mutant and wild-type CK genes were tagged with FLAG in the mammalian expression vector and transfected into COS-7 cells. Both genes were transcribed at an approximately equal level, as confirmed by RT-PCR of the m RNA of each transfectant, consistent with the fact that these two genes were driven by the strong cytomegalovirus promoter. In the immunohistochemical study, however, cells transfected with FLAG-tagged mutant CK cDNA did not show any positive staining by the monoclonal FLAG antibody, whereas cells transfected with the wild-type fusion gene showed positive staining. On Western blotting, positive bands were detected corresponding to the size of pro-CK, although the density of the mutant fusion gene product was significantly reduced compared to that of the wild-type product. Thus, expression of the mutant protein was markedly reduced, and it was probably below the detection limit of immunohistochemistry.

Some experiments have suggested that disruption of the hydrophobic core by either charged or helix-breaking residues mostly leads to a more or less severe kinetic defect in translocation, but rarely blocks export altogether (23, 24). In the present case, the replacement of Leu9 by a helical-breaking residue, Pro, is expected to impair translocation of the nascent preproenzyme across the endoplasmic reticulum membrane, which would be followed by its degradation.

Some mutations in human signal sequences have been reported to have a direct correlation with defective protein synthesis and pathological status (25, 26, 27). Signal peptide mutations have been described for prepro-PTH and bilirubin-UDP-glucuronosyltransferase, which were similar to the mutation found in patient 4, and these are reported to cause disruption of the hydrophobic core of the signal peptide (25, 26). Such mutations have mainly been found in secretory proteins or membrane proteins, and the effect of a mutation in the signal peptide sequence on the intracellular transport of a lysosomal enzyme is not well understood. In the case of lysosomal disease, there have only been two reports on mutations in the signal peptide sequence. A missense mutation, resulting in Pro to Arg substitution at amino acid 5 in the hydrophobic core of the signal peptide of {alpha}-L-fucosidase, has been reported in a patient with fucosidosis, an autosomal recessive lysosomal storage disease (28). The other report was of a missense mutation in an atypical variant of Fabry’s disease, resulting in substitution at amino acid 20 in the signal peptide of {alpha}-galactosidase (29).

In conclusion, we have analyzed the structure of the CK gene in four Japanese patients with pycnodysostosis and identified mutations that explained the pathogenesis of the disease. Although one had a mutation identical to that previously reported (8, 9), the others had novel mutation sites. One of them had a missense mutation at the CK signal peptide that disrupted the function of the signal peptide. This is the first report of signal peptide dysfunction due to an amino acid alteration as one of the genotypic subtypes of pycnodysostosis.

Received July 16, 1999.

Revised August 31, 1999.

Accepted September 9, 1999.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Andren L, Dymling JF, Hogeman KE, Wendeberg B. 1962 Osteopetrosis acro-osteolytica: a syndrome of osteopetrosis, acro-osteolysis and open sutures of the skull. Acta Chir Scand. 124:496–507.
  2. Maroteaux P, Lamy M. 1965 The malady of Toulouse-Lautrec. JAMA. 191:715–717.
  3. Edelson JG, Obad S, Geiger R, On A, Artul HJ. 1992 Pycnodysostosis: orthopedic aspects with a description of 14 new cases. Clin Orthop. 280:263–276.
  4. Gelb BD, Edelson JG, Desnick RJ. 1995 Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat Genet. 10:235–237.[CrossRef][Medline]
  5. Polymeropoulos MH, Ortiz de Luna RI, Ide SE, et al. 1995 The gene for pycnodysostosis maps to human chromosome 1cen-21. Nat Genet. 10:238–239.[CrossRef][Medline]
  6. Gelb BD, Shi G-P, Chapman HA, Desnick RJ. 1996 Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 273:1236–1238.[Abstract]
  7. Johnson MR, Polymeropolus MH, Vos HL, Ortiz de Luna RI, Francomano CA. 1996 A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. 6:1050–1055.[Abstract/Free Full Text]
  8. Gelb BD, Willner JP, Dunn TM, et al. 1998 Paternal uniparental disomy for chromosome 1 revealed by molecular analysis of a patient with pycnodysostosis. Am J Hum Genet. 62:848–854.[CrossRef][Medline]
  9. Hou W-H, Brömme D, Zhao Y, et al. 1999 Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J Clin Invest. 103:731–738.[Medline]
  10. Bossard MJ, Tomaszek TA, Thompson SK, et al. 1996 Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 271:12517–12524.[Abstract/Free Full Text]
  11. Kafienah W, Brömme D, Buttle DJ, Croucher LJ, Hollander AP. 1998 Human cathepsin K cleaves native type I and II collagens at N-teminal end of the triple helix. Biochem J. 331:727–732.
  12. Tezuka K, Tezuka Y, Maejima A, et al. 1994 Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem. 269:1106–1109.[Abstract/Free Full Text]
  13. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. 1995 Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun. 206:89–96.[CrossRef][Medline]
  14. Li YP, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko PJ. 1995 Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res. 10:1197–1202.[Medline]
  15. Drake FH, Dodds RA, James IE, et al. 1996 Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem. 271:12511–12516.[Abstract/Free Full Text]
  16. Brömme D, Okamoto K. 1995 Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary, molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler. 376:379–384.[Medline]
  17. Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ. 1995 Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett. 357:129–134.[CrossRef][Medline]
  18. Saftig P, Hunziker E, Wehmeyer O, et al. 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 95:13453–13458.[Abstract/Free Full Text]
  19. Kukita A, Kukita T, Shin J-H, Kohashi O. 1993 Induction of mononuclear precursor cells with osteoclastic phenotypes in a rat bone marrow culture system depleted of stromal cells. Biochem Biophys Res Commun. 196:1383–1389.[CrossRef][Medline]
  20. Torituka Y, Nakamura N, Lee SB, Hashimoto, et al. 1997 Osteoclastogenesis in iliac bone marrow of patients with reumatoid arthritis. J Reumatol. 24:91690–1696.
  21. Taylor JW, Ott J, Eckstein F. 1985 The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA. Nucleic Acids Res. 13:8765–8785.[Abstract/Free Full Text]
  22. Schatz G, Dobberstein B. 1996 Common principles of protein translocation across membranes. Science. 271:1519–1526.[Abstract]
  23. von Heijne G. 1990 The signal peptide. J. Membr Biol. 115:195–201.[CrossRef][Medline]
  24. Fikes JD, Bankaitis VA., Ryan JP, Bassford PJ. 1987 Mutational alterations affecting the export competence of a truncated but fully functional maltose-binding protein signal peptide. J Bacteriol. 169:2345–2351.[Abstract/Free Full Text]
  25. Arnold A, Horst SA, Gardella TJ, Baba H, Levine MA, Kronenberg HM. 1990 Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest. 86:1084–1087.
  26. Seppen J, Steenken E, Lindhout D, Bosma PJ, Oude Elferink RPJ. 1996 A mutation which disrupts the hydrophobic core of the signal peptide of bilirubin UDP-glucuronosyltransferase, an endoplasmic reticulum membrane protein, causes Crigler-Najjar type II. 1996. FEBS Lett. 390:294–298.[CrossRef][Medline]
  27. Ito M, Oiso Y, Murase T, et al. 1993 Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause of familial central diabetes inspidus. J Clin Invest. 91:2565–2571.
  28. Cragg H, Williamson M, Young E, et al. 1997 Fucosidosis: genetic and biochemical analysis of eight cases. J Med Genet. 34:105–110.[Abstract/Free Full Text]
  29. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 333:288–293.



This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
N. Fratzl-Zelman, A. Valenta, P. Roschger, A. Nader, B. D. Gelb, P. Fratzl, and K. Klaushofer
Decreased Bone Turnover and Deterioration of Bone Structure in Two Cases of Pycnodysostosis
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1538 - 1547.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
M. Jiang, T. Lamminen, P. Pakarinen, J. Hellman, P. Manna, R. J. Herrera, and I. Huhtaniemi
A novel Ala-3Thr mutation in the signal peptide of human luteinizing hormone {beta}-subunit: potentiation of the inositol phosphate signalling pathway and attenuation of the adenylate cyclase pathway by recombinant variant hormone
Mol. Hum. Reprod., March 1, 2002; 8(3): 201 - 212.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Ringpfeil, M. G. Lebwohl, A. M. Christiano, and J. Uitto
Pseudoxanthoma elasticum: Mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter
PNAS, May 23, 2000; 97(11): 6001 - 6006.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujita, Y.
Right arrow Articles by Ochi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, Y.
Right arrow Articles by Ochi, T.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals